The effects of blocking angiotensin receptors on early stages of diabetic nephropathy

Background: This study aimed to investigate the beneficial effects of angiotensin receptor blockers (ARBs) on markers of endothelial function in patients with early stage of diabetic nephropathy (DN). Methods: This cross-sectional study was conducted on 32 participants with IDDM from January 2010 un...

Full description

Bibliographic Details
Main Authors: Alaleh Gheissari, Shaghayegh H Javanmard, Roohollah Shirzadi, Masood Amini, Nooshin Khalili
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2012-01-01
Series:International Journal of Preventive Medicine
Subjects:
Online Access:http://www.ijpvmjournal.net/article.asp?issn=2008-7802;year=2012;volume=3;issue=7;spage=477;epage=482;aulast=Gheissari
_version_ 1818215341347569664
author Alaleh Gheissari
Shaghayegh H Javanmard
Roohollah Shirzadi
Masood Amini
Nooshin Khalili
author_facet Alaleh Gheissari
Shaghayegh H Javanmard
Roohollah Shirzadi
Masood Amini
Nooshin Khalili
author_sort Alaleh Gheissari
collection DOAJ
description Background: This study aimed to investigate the beneficial effects of angiotensin receptor blockers (ARBs) on markers of endothelial function in patients with early stage of diabetic nephropathy (DN). Methods: This cross-sectional study was conducted on 32 participants with IDDM from January 2010 until May 2011 in Isfahan, Iran. The participants were candidate for receiving ARBs or angiotensin-converting enzyme inhibitors (ACEIs) to decrease microalbuminuria. The inclusion criteria were as follows: the age of onset of insulin-dependent diabetes mellitus (IDDM)less than 15 years; normal glomerular filtration rate (GFR); normal blood pressure; normal cardiovascular examination; negative urine culture, receiving no medications except insulin. Microalbuminuria was measured in two fasting urine samples with a sampling interval of at least 1-2 months by ELISA method. Patients with two abnormal results were included. Microalbumin to creatinin ratio equal to or more than 30 mg/gm was considered abnormal. The fasting blood samples to determine serum nitric oxide (NO) and vascular cell adhesion molecule (VCAM) were obtained at the time 0 (before starting the study), and after 2 months of receiving ARBmedication. Valsartan tablet (Diovan, Novartis Company) with a dose of 1 mg/kg/day up to 80 mg/day in a single dose was administered. Results: Urine microalbumin to creatinin ratio after valsartan consumption was lower than microalbumin level before the medication, P < 0.05. After valsartan consumption, serum VCAM-1 level reduced and NO level increased significantly, P < 0.05. Conclusion: Angiotensin receptor blockers may reduce VCAM-1 and microalbuminuria and may increase NO levels in early stages of DN. Thus administration of ARBs might be considered even in early stages of DN.
first_indexed 2024-12-12T06:34:32Z
format Article
id doaj.art-af7dd2a717d340249a45341c31c6d84a
institution Directory Open Access Journal
issn 2008-7802
2008-8213
language English
last_indexed 2024-12-12T06:34:32Z
publishDate 2012-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series International Journal of Preventive Medicine
spelling doaj.art-af7dd2a717d340249a45341c31c6d84a2022-12-22T00:34:30ZengWolters Kluwer Medknow PublicationsInternational Journal of Preventive Medicine2008-78022008-82132012-01-0137477482The effects of blocking angiotensin receptors on early stages of diabetic nephropathyAlaleh GheissariShaghayegh H JavanmardRoohollah ShirzadiMasood AminiNooshin KhaliliBackground: This study aimed to investigate the beneficial effects of angiotensin receptor blockers (ARBs) on markers of endothelial function in patients with early stage of diabetic nephropathy (DN). Methods: This cross-sectional study was conducted on 32 participants with IDDM from January 2010 until May 2011 in Isfahan, Iran. The participants were candidate for receiving ARBs or angiotensin-converting enzyme inhibitors (ACEIs) to decrease microalbuminuria. The inclusion criteria were as follows: the age of onset of insulin-dependent diabetes mellitus (IDDM)less than 15 years; normal glomerular filtration rate (GFR); normal blood pressure; normal cardiovascular examination; negative urine culture, receiving no medications except insulin. Microalbuminuria was measured in two fasting urine samples with a sampling interval of at least 1-2 months by ELISA method. Patients with two abnormal results were included. Microalbumin to creatinin ratio equal to or more than 30 mg/gm was considered abnormal. The fasting blood samples to determine serum nitric oxide (NO) and vascular cell adhesion molecule (VCAM) were obtained at the time 0 (before starting the study), and after 2 months of receiving ARBmedication. Valsartan tablet (Diovan, Novartis Company) with a dose of 1 mg/kg/day up to 80 mg/day in a single dose was administered. Results: Urine microalbumin to creatinin ratio after valsartan consumption was lower than microalbumin level before the medication, P < 0.05. After valsartan consumption, serum VCAM-1 level reduced and NO level increased significantly, P < 0.05. Conclusion: Angiotensin receptor blockers may reduce VCAM-1 and microalbuminuria and may increase NO levels in early stages of DN. Thus administration of ARBs might be considered even in early stages of DN.http://www.ijpvmjournal.net/article.asp?issn=2008-7802;year=2012;volume=3;issue=7;spage=477;epage=482;aulast=GheissariAngiotensin receptor blockerdiabetic nephropathyendothelial dysfunctionvalsartan
spellingShingle Alaleh Gheissari
Shaghayegh H Javanmard
Roohollah Shirzadi
Masood Amini
Nooshin Khalili
The effects of blocking angiotensin receptors on early stages of diabetic nephropathy
International Journal of Preventive Medicine
Angiotensin receptor blocker
diabetic nephropathy
endothelial dysfunction
valsartan
title The effects of blocking angiotensin receptors on early stages of diabetic nephropathy
title_full The effects of blocking angiotensin receptors on early stages of diabetic nephropathy
title_fullStr The effects of blocking angiotensin receptors on early stages of diabetic nephropathy
title_full_unstemmed The effects of blocking angiotensin receptors on early stages of diabetic nephropathy
title_short The effects of blocking angiotensin receptors on early stages of diabetic nephropathy
title_sort effects of blocking angiotensin receptors on early stages of diabetic nephropathy
topic Angiotensin receptor blocker
diabetic nephropathy
endothelial dysfunction
valsartan
url http://www.ijpvmjournal.net/article.asp?issn=2008-7802;year=2012;volume=3;issue=7;spage=477;epage=482;aulast=Gheissari
work_keys_str_mv AT alalehgheissari theeffectsofblockingangiotensinreceptorsonearlystagesofdiabeticnephropathy
AT shaghayeghhjavanmard theeffectsofblockingangiotensinreceptorsonearlystagesofdiabeticnephropathy
AT roohollahshirzadi theeffectsofblockingangiotensinreceptorsonearlystagesofdiabeticnephropathy
AT masoodamini theeffectsofblockingangiotensinreceptorsonearlystagesofdiabeticnephropathy
AT nooshinkhalili theeffectsofblockingangiotensinreceptorsonearlystagesofdiabeticnephropathy
AT alalehgheissari effectsofblockingangiotensinreceptorsonearlystagesofdiabeticnephropathy
AT shaghayeghhjavanmard effectsofblockingangiotensinreceptorsonearlystagesofdiabeticnephropathy
AT roohollahshirzadi effectsofblockingangiotensinreceptorsonearlystagesofdiabeticnephropathy
AT masoodamini effectsofblockingangiotensinreceptorsonearlystagesofdiabeticnephropathy
AT nooshinkhalili effectsofblockingangiotensinreceptorsonearlystagesofdiabeticnephropathy